Availability of anti-rabies vaccine and rabies immunoglobulin in Indian health facilities: a nationwide cross-sectional health facility survey
- PMID: 40584691
- PMCID: PMC12205764
- DOI: 10.1016/j.lansea.2025.100608
Availability of anti-rabies vaccine and rabies immunoglobulin in Indian health facilities: a nationwide cross-sectional health facility survey
Abstract
Background: Ensuring the uninterrupted availability of the anti-rabies vaccine (ARV) and rabies immunoglobulin (RIG) in health facilities is crucial to achieve the global target of zero dog-mediated human rabies deaths by 2030. This study aimed to estimate the availability of ARV and RIG across health facilities in India.
Methods: We conducted a nationwide health facility-based, cross-sectional study across 60 districts selected by multistage probability sampling from 15 Indian states. In each district, we selected nine health facilities. We interviewed staff involved in the rabies control program in each of the selected health facilities, and abstracted and physically validated information on the availability of ARV and RIG.
Findings: Of the 534 health facilities surveyed, 467 (87.5%) were public sector health facilities. ARV was available in 372 (79.7%, 95% CI: 75.7%-83.2%) public sector health facilities, ranging from 60.0% to 93.2% in different geographic regions. Availability of ARV was lowest in Urban Primary Healthcare Centres (UPHCs) (58.9%, 95% CI: 45.0%-71.9%). RIG was available in 95 (20.3%, 95% CI: 16.8%-24.3%) public sector health facilities, with the highest availability in southern states (27/88, 30.7%). The availability of RIG ranged from 1.8% (95% CI: 16.8%-24.3%) in UPHCs to 69.2% (95% CI: 48.2%-85.7%) in medical college hospitals.
Interpretation: Considerable geographic and facility-level variations exist in the availability of ARV and RIG across India. Bridging the gap in the availability of ARV and RIG should be prioritised to achieve the goal of zero-dog-mediated human rabies deaths by 2030.
Funding: Indian Council of Medical Research.
Keywords: Bites and stings; Health facility; Immunoglobulin; Monoclonal antibody; Rabies; Vaccine.
© 2025 The Author(s).
Conflict of interest statement
We declare no competing interests.
Figures



References
-
- Rabies. https://www.who.int/health-topics/rabies [cited 2024 Sep 10]. Available from:
-
- Thangaraj J.W.V., Krishna N.S., Devika S., et al. Estimates of the burden of human rabies deaths and animal bites in India, 2022–23: a community-based cross-sectional survey and probability decision-tree modelling study. Lancet Infect Dis. 2024;0(0) https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(24)00490... [cited 2024 Nov 12] Available from: - PubMed
-
- United Against Rabies A significant public health problem. https://www.unitedagainstrabies.org/a-significant-public-health-problem/ [cited 2024 Aug 5] Available from:
-
- Nadal D., Bote K., Abela B. Is there hope to reach the Zero by 30 target for dog-mediated human rabies? Lancet Glob Health. 2023;11(11):e1682–e1683. - PubMed
-
- National Rabies Control Programme (NRCP) https://rabiesfreeindia.mohfw.gov.in/Programme-Strategies [cited 2024 Jul 25]. Available from:
LinkOut - more resources
Full Text Sources
Miscellaneous